Hemcheck Sweden (HEMC.ST) Stock Analysis & AI Equity Report
Hemcheck Sweden (HEMC.ST) overview
Hemcheck Sweden (HEMC.ST) stock analysis and AI equity research. For the latest completed financial year, 2022, Hemcheck Sweden reported revenue of SEK 1.3m and operating profit of SEK -14.9m; the year-end share price was 0.19 SEK and market capitalisation was SEK 3.0m. Hemcheck Sweden is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Hemcheck Sweden's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Hemcheck Sweden
Hemcheck Sweden AB (publ) develops and commercializes point-of-care products for detecting hemolysis in blood samples. Its Helge concept includes single-use tests for vacuum tubes and blood gas syringes, together with a reader and optional display. The company is based in Karlstad and serves healthcare settings where timely blood sample quality control matters.
Generate the Hemcheck Sweden report
Hemcheck Sweden is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Hemcheck Sweden and represent the latest completed financial year (2022). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.